Amgen's guidance comes up short, but migraine drug sales show promise

Amgen Inc. (NASDAQ:AMGN) reported 4Q18 and 2018 earnings that beat consensus estimates on Tuesday but the bellwether’s 2019 guidance fell shy of analyst expectations.

The company said it expects 2019 non-GAAP EPS of $13.10-$14.30, below consensus of $14.57.

Read the full 382 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE